Bowman and Brooke’s Post

#Litigation attorney Eric Alexander authored an article featured in Drug & Device Law analyzing #liability theories on decisions to continue or halt sales of #prescriptiondrugs, using the #Fabrazyme shortage litigation as a case study. He critiques the merits of “stop selling” and “keep selling” claims, questioning whether #plaintiffs’ evolving allegations over time should allow cases to proceed. His analysis offers a strong skepticism of these emerging liability theories against #pharmaceutical companies. Click here to read and learn more. #productliability

Attention to all legal professionals and law firms! 📢 With the Ozempic weight loss MDL looming, law firms have a unique opportunity to make a real impact. By proactively purchasing leads, you position your firm at the forefront of this evolving legal landscape. 💼⚖️ Don't wait for the competition to seize the opportunity—take action now to secure your firm's success. Ozempic has been hailed as a breakthrough in weight loss treatment, but it's not without its controversies. If your firm specializes in representing individuals affected by pharmaceutical issues, our Ozempic web leads are the solution you've been searching for. Ready to elevate your practice with Ozempic web leads? Don't miss out on this opportunity to expand your client base and make a meaningful impact in pharmaceutical litigation. Contact us today to learn more about our Ozempic web leads and how they can benefit your firm. Let's work together to achieve justice for those affected by pharmaceutical issues. Call s at (202) 773-9477 Email us at [email protected] www.rainmaker-legal.com #Ozempic #WebLeads #PharmaceuticalLitigation #LawFirms #rainmakerlegalleads #LegalServices⁶

Plaintiff's #personalinjury attorney Shannon Clark shares best practices for manufacturers in his latest article, "Mitigating Product Liability Risks for Manufacturers," published by the Phoenix Business Journal. https://lnkd.in/gqQeEpV4 From consumer goods to pharmaceuticals, product defect claims are rising nationally and locally. So how can manufacturers, suppliers, and distributors reduce their risks and avoid costly lawsuits? Read Shannon's article for insights and best practices from a plaintiff's counsel perspective on making safer products. #ProductLiability #Manufacturing

In a significant legal development, MSP Recovery Law Firm LLC, representing LifeWallet, has secured a $3.1 million settlement in an antitrust case involving a pharmaceutical manufacturer. The case, which alleged that the drug maker had unlawfully increased the price of a medication in violation of antitrust laws, marks a notable victory for LifeWallet’s ongoing efforts to hold healthcare entities accountable for unfair practices... #antitrust #antitrustlaw #competitionlaw #pharmaceutical

Plaintiff's #personalinjury attorney Shannon Clark shares best practices for manufacturers in his latest article, "Mitigating Product Liability Risks for Manufacturers," published by the Phoenix Business Journal. https://lnkd.in/gqQeEpV4 From consumer goods to pharmaceuticals, product defect claims are rising nationally and locally. So how can manufacturers, suppliers, and distributors reduce their risks and avoid costly lawsuits? Read Shannon's article for insights and best practices from a plaintiff's counsel perspective on making safer products. #ProductLiability #Manufacturing

Further updates: Amgen plans launch of Eylea biosimilar after court ruling 🚀 Amgen is set to launch its biosimilar of Regeneron’s Eylea, called Pavblu, following a court ruling that lifted a temporary injunction. This strategic move comes amid ongoing litigation, with Regeneron claiming patent infringement. The favorable court decision puts Amgen in a strong position relative to other generic competitors. Here are a few key anticipations: 1. Settlement Potential: The ruling could increase the likelihood of a settlement with Regeneron, as both parties may prefer to avoid the costs of prolonged litigation and explore a more collaborative approach. 2. Mutual Benefits: This scenario could benefit both companies—enabling Amgen to solidify its market entry while allowing Regeneron to effectively protect its interests. 3. Strategic Shifts: Regeneron's active promotion of a higher-dose version of Eylea illustrates its commitment to safeguarding its market position in the face of rising competition from multiple approved biosimilars. Encouraging patients to switch to this new version reflects a strategic pivot aimed at maintaining revenue streams. Exciting developments in the biosimilars landscape ahead! #Biotech #Biosimilars #HealthcareInnovation

Some kind words from one of our partners, Doug Snyder, the former Chief Legal Officer at GW Pharmaceuticals, Actelion, and Eisai. "As the former Chief Legal Officer at Eisai, Actelion, and GW Pharmaceuticals, I have had the pleasure of working with Lovell since their inception in 2010. Their team of attorneys with diverse practice areas offers exceptional and creative contract support that is both friendly and knowledgeable. Lovell’s cost-effective approach to everyday contract needs is unparalleled, making them an indispensable partner for global pharmaceutical companies. I wholeheartedly recommend Lovell for their extraordinary work." Team up with us at LovellLawGroup.com #corporatelawfirm #lawfirm #contracts #contractspecialists #contractsupport #contractmanagement #outsourcedcontracts #lifescience #lifesciencecontract #industryneutral #industryneutralcontract #legalservices #legal #inhouse #attorneys #contractprocess #contractingprocess #lovell

Legal counsels, what do you find effective in mitigating the headaches of legal disputes? Explore how a leading pharmaceutical company leverages early case assessment in eDiscovery to gain strategic advantages and cut costs. #EarlyCaseAssessment #ediscovery #LegalReview #Litigation #DataManagement

Preliminary Injunction Denied Against Amgen in Aflibercept BPCIA Litigation. Here an intriguing question rises: what makes Amgen the unique spark in a sea of sameness? In a recent turn of events, Regeneron’s request for a preliminary injunction against Amgen's product launch has been denied, despite similar requests being granted against other companies like Samsung Bioepis, Formycon, Celltrion, and Mylan. In BPCIA (Biologics Price Competition and Innovation Act) litigation, a preliminary injunction can be granted based on several factors, including: likelihood of success on the merits, irreparable harm, balance of equities, public interest, compliance with BPCIA procedures and patent validity issues. Each of these grounds provides a framework for courts to evaluate the appropriateness of an injunction. However, what specific factors allowed Amgen to stand out? As we dig deeper into this case, initial comparisons of product attributes suggest that Regeneron may struggle to establish that Amgen’s product infringes the patent-in-suit. This insight opens the door for further exploration into how Amgen navigated the complexities of BPCIA litigation differently than its competitors. Keeping track of further developments in this litigation may unpack the unique elements of Amgen’s position and what it means for the future of biologics competition! Any insights or comments from readers of this post are welcomed.

Procopio’s Life Sciences Litigation Practice and three of its attorneys were recognized by Patexia for outstanding performance in Hatch-Waxman/ANDA Litigation in multiple categories. In addition, Procopio was named a Top 10 law firm out of more than 220 firms. Partners Jeremy Edwards and Steven Maddox ranked in the Top 25 out of nearly 2,000 attorneys, and Senior Counsel Brett Garrison ranked in the Top 100. Jeremy, Steven and Brett are all based in Procopio’s Washington, D.C., office. Each year Patexia evaluates and ranks law firms and attorneys in various IP fields based on their performance, activity and success across a five-year period. The 2024 ANDA Intelligence Report analyzed more than 1,400 ANDA (Abbreviated New Drug Application) cases involving nearly 150 judges and more than 1,700 patents involving more than 460 pharmaceutical companies. Patexia notes the Hatch-Waxman/ANDA litigation space is highly competitive, with many law firms struggling to stand out and pharmaceutical companies searching for the best counsel. Learn more. https://lnkd.in/gkfT-d3f